Abstract: An embodiment electric vehicle drive apparatus for decreasing a drive speed of a motor and transferring the decreased drive speed to an output shaft is provided. The apparatus includes a first planetary gear set including three first planetary gear elements in which a first element is connected to the motor and a second element is connected to a first output shaft, a second planetary gear set including three second planetary gear elements in which a first element is connected to a third element of the three first planetary gear elements, a second element is connected to a second output shaft, and a third element is fixed, and a third planetary gear set including three third planetary gear elements in which first and second elements are connected to two elements of the three first planetary gear elements, respectively, and a third element is connected to a torque vectoring motor.

Abstract: The present invention relates to an electrolyte composition including a lithium salt; a non-aqueous organic solvent; a compound represented by a specific formula; and a perfluoropolyether oligomer, a gel polymer electrolyte including a polymer network which is formed by a polymerization reaction of the electrolyte composition, and a lithium secondary battery including the same.

Abstract: A seat for a vehicle with a cushion tip-up and down function is provided. The seat is configured such that a cushion leg provided in a cushion is held, in a fitted manner, by a support spring of a support structure provided in a seat base, and when the cushion is rotated, the cushion leg is allowed to be folded and ejected by being automatically rotated, thereby improving the convenience of use.

Abstract: The present disclosure relates to a vehicle rear seat including: a center seat; and side seats located on the left and right of the center seat, wherein, the center seat is capable of protruding by moving the center seat forward with respect to the side seats, and in the state in which the center seat protrudes forward, it is possible to increase an inter-passenger distance so that physical contact between the passenger of the center seat and the passenger of each of the side seats can be prevented as much as possible.

Abstract: Provided is a desalination device using a solvent extraction method, comprising: a first mixing tank composed of a feed water inlet into which feed water comprising salt ions and water molecules flows, a first solvent inlet into which a first solvent selectively reacting more with the water molecules than with the salt ions flows, a first mixing tank body in which the feed water and the first solvent are mixed so as to form a mixed water, and a mixed water outlet through which the mixed water is discharged; a first separation tank composed of a mixed water inlet which communicates with the mixed water outlet so that the mixed water flows therein, a first separation tank body in which brine containing salt ions of the feed water and first treatment water formed from mixing the water molecules of the feed water and the first solvent of the mixed water are separated by layer, and a first treatment water outlet through which the first treatment water is discharged; a second mixing tank composed of a first treatme

Abstract: According to an aspect of the present disclosure, there is provided a method of controlling a power amplifier in a low-orbit satellite network, the method comprising: communicating, by a terminal, with a satellite; setting an initial applied voltage and frequency; receiving orbit information from the satellite; and updating the initial applied voltage according to the orbit information and network environment.

Abstract: A semiconductor nanoparticle including a first semiconductor nanocrystal including silver, indium, gallium, and sulfur, and a semiconductor nanoparticle including a second semiconductor nanocrystal including zinc, gallium, and sulfur, a method of manufacturing the same, and an electronic device including the same. The semiconductor nanoparticle is configured to emit a green light. The green light has a peak emission wavelength of about 500 nanometers to about 580 nanometers. In the semiconductor nanoparticle, a molar ratio of zinc to indium is about 0.1:1 to about 10:1.

Abstract: A semiconductor nanoparticle, a method of manufacturing the semiconductor nanoparticle, and an electronic device including the nanoparticle are provided. The semiconductor nanoparticle includes silver, indium, gallium, and sulfur, wherein the semiconductor nanoparticle is configured to emit a green light, wherein the semiconductor nanoparticle has a relative mole value of zinc as defined by Equation 1 that is greater than or equal to about 0.25 and less than or equal to about 0.9: Relative ? mole ? value ? of ? zinc = [ Zn ] / ( [ Ag ] + [ In ] + [ Ga ] + [ Zn ] ) Equation ? 1 wherein, in Equation 1, [Ag], [In], [Ga], and [Zn] are molar amounts of the silver, the indium, the gallium, and the zinc in the semiconductor nanoparticle, respectively, and wherein a mole ratio of gallium to indium is greater than about 2.5:1 and less than about 5.6:1.

Abstract: The method for predicting Alzheimer's disease-related biomarkers according to the present disclosure involves a method executed by one or more processors of a computing device. The method comprises collecting medical images of a subject, preprocessing the collected medical images to generate training data, training a biomarker prediction model using the generated training data and the subject's demographic and clinical information, where the training includes assigning weights to the training data, and predicting Alzheimer's disease-related biomarkers for a patient using the trained biomarker prediction model.

Abstract: Provided are a negative electrode for a lithium secondary battery having reinforced insulating properties, which comprises a negative electrode active material layer; and a ceramic separating layer formed on the negative electrode active material layer, wherein the negative electrode active material layer has an arithmetic average surface roughness (Ra) of 0.01 ?m to 0.3 ?m, and the ceramic separating layer has a thickness of 1 ?m to 30 ?m, and a lithium secondary battery comprising the same.

Abstract: A fusion protein contains an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Abstract: A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Abstract: A vehicle control apparatus and method for moving and parking a vehicle double-parked around a parked vehicle are provided. The vehicle control apparatus includes a detector that detects departure intention information of the first vehicle and surrounding information of the second vehicle. A vehicle controller controls autonomous movement of the second vehicle and a processor detects a departure intention of the first vehicle based on the departure intention information. A movement plan of the second vehicle is generated based on the surrounding information when departure intention is detected and the vehicle controller moves the second vehicle based on the movement plan.

Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.

Abstract: An apparatus and a method provide a four-dimensional effect to a driver and/or passengers of a vehicle. The apparatus includes a first vehicle controller that analyzes data of content played in an electronic device, sets four-dimensional effect information and generates vehicle control information for realizing the four-dimensional effect according to the set four-dimensional effect information, and a second vehicle controller that performs vehicle control based on the vehicle control information in consideration of a driving status of a vehicle.

Abstract: A vehicle control apparatus and method for moving and parking a vehicle double-parked around a parked vehicle are provided. The vehicle control apparatus includes a detector that detects departure intention information of the first vehicle and surrounding information of the second vehicle. A vehicle controller controls autonomous movement of the second vehicle and a processor detects a departure intention of the first vehicle based on the departure intention information. A movement plan of the second vehicle is generated based on the surrounding information when departure intention is detected and the vehicle controller moves the second vehicle based on the movement plan.

Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.

Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.